L-theanine In The Adjunctive Treatment Of Generalized Anxiety Disorder: A Double-blind, Randomised, Placebo-controlled Trial
Notes for this study:
||Montgomery-Asberg Depression Rating Scale. Mean and SD. Placebo: before 11.9 (3.86), after 9.17 (6.86, 11.5). Theanine: before 12.9 (2.85), after 11.3 (9.08, 13.5).
|Number of Subjects
||18-29, 30-44, 45-64, 65+
In a randomized, double-blind, placebo-controlled trial 46 participants with generalized anxiety disorder were allocated to take 450 mg of theanine (in two divided doses of the course of the day, or placebo for 8 weeks.
Funding issues for this study:
The primary outcomes were anxiety and insomnia. There were no statistically significant or notable differences between groups for anxiety outcomes. There was a small advantage of theanine for insomnia, but the difference wasn't statistically significant. Additionally, the change in depression rating wasn't notably different.
"JS is supported by an NHMRC Clinical Research Fellowship (APP
1125000). The study was co-sponsored by FIT-BioCeuticals. No funding
source was involved in the design, statistical analysis or preparation of
this manuscript. Study sponsors similarly played no role in the decision
to submit this manuscript for publication."